Screener
Azenta AZTA Multiomics — Operating Income (Loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Azenta in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Azenta’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q3 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054295
| Multiomics | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Nine Months Ended June 30, 2026 | Nine Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total revenue | $72,889 | $66,235 | $203,811 | $196,054 |
| Less: Adjusted cost of revenue | 38,970 | 39,151 | 115,648 | 110,939 |
| Less: Adjusted operating expenses | 34,267 | 31,042 | 102,940 | 96,916 |
| Adjusted operating loss | $(348) | $(3,958) | $(14,777) | $(11,801) |
| Other Information | ||||
| Depreciation Expense | $2,647 | $4,024 | $10,588 | $11,346 |
Item 1. Financial Statements
FAQ
- What is Azenta's multiomics — operating income (loss)?
- Azenta (AZTA) reported multiomics — operating income (loss) of -$348K in Q2 2026.
- How has Azenta's multiomics — operating income (loss) changed year-over-year?
- Azenta's multiomics — operating income (loss) increased by 91.2% year-over-year, from -$3.96M to -$348K.
- What does multiomics — operating income (loss) mean?
- The profit or loss generated by the Multiomics segment after deducting both the cost of revenue and operating expenses from total segment revenue. This represents the core operational performance of the business unit before interest, taxes, and corporate-level allocations. It is a key indicator of the segment's ability to generate sustainable returns from its core activities.
Ask your AI about Azenta's multiomics — operating income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude